Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of Pharma Derasse BSI is 1.8% (moderate). The 2025 annual accounts show equity of €121k and a net result of €9k. Equity remains stable across the filed fiscal years (±1.8% per year). Its solvency ranks better than 54% of 249 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 4 annual accounts.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneStatistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Filing behaviour
From the deposit records, complete market-wide| Year closed | Due by | Filed | Variance | Reference |
|---|---|---|---|---|
| 31-12-2025 | 31-07-2026 | 26-05-2026 | 66 d early | 2026-00121187 |
| 31-12-2024 | 31-07-2025 | 21-05-2025 | 71 d early | 2025-00101188 |
| 31-12-2023 | 31-07-2024 | 05-06-2024 | 56 d early | 2024-00111166 |
| 31-12-2022 | 31-07-2023 | 05-06-2023 | 56 d early | 2023-00106170 |
Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.
Trust signals
2 signalsAdministrative Flags
Financials
Annual accounts & ratios
Source: NBB · 2025How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 15.9% | 13.9% | |
| Net result | €9k | €19k | |
| Equity | €121k | €95k | |
| Gross operating margin | €125k | €323k | |
| Staff costs | €43k | €281k |
Show 12 other metrics
| Fiscal year | 2025 |
|---|---|
| Deposit | volledig |
| Revenue | - |
| EBITDA | €80k |
| Net profit | €9k |
| Cash flow | €67k |
| Staff costs | €43k |
| Income taxes | €3k |
| Dividends | - |
| Total assets | €763k |
| Equity | €121k |
| Debt | €642k |
| of which ≤ 1y | €260k |
| of which > 1y | €382k |
| Working capital | €-115k |
| Employees (FTE) | 0.6 |
| 2025 | |
|---|---|
| Current ratio | 0.56 |
| Quick ratio | 0.30 |
| Working capital ratio | -15.0% |
| Solvency | 15.9% |
| Debt / equity | 5.31 |
| Long-term debt ratio | 3.16 |
| Interest coverage | 8.45 |
| Gross margin | - |
| Net margin | - |
| ROA | 1.2% |
| ROE | 7.5% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (24 line items)
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €763k |
| Fixed assets | 21/28 | €618k |
| Intangible fixed assets | 21 | €60k |
| Tangible fixed assets | 22/27 | €558k |
| Current assets | 29/58 | €145k |
| Stocks & contracts in progress | 3 | €68k |
| Amounts receivable within one year | 40/41 | €46k |
| Cash & bank | 54/58 | €26k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €763k |
| Equity | 10/15 | €121k |
| Contributions / capital | 10/11 | €120k |
| Accumulated profits (losses) | 14 | €966 |
| Amounts payable | 17/49 | €642k |
| Amounts payable after one year | 17 | €382k |
| Amounts payable within one year | 42/48 | €260k |
| Trade debts payable within one year | 44 | €73k |
| Income statement | ||
| Gross operating margin | 9900 | €125k |
| Operating result | 9901 | €22k |
| Financial income | 75 | €16 |
| Financial charges | 65 | €9k |
| Result before taxes | 9903 | €12k |
| Income taxes | 67/77 | €3k |
| Net result for the period | 9904 | €9k |
| Result to be appropriated | 9905 | €9k |
Health barometer
FY 2025 · computedThe full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →Structure & network
Locations & real estate
Registered office
on the map · from the address registerEstablishment units
1 locationReal-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25078B0048/00E002 | Wallonia | 1,086 m² | 1 · 116 m² | 9.6 m · 2 fl. |
Publications
Lifecycle & Insolvency Signals
Belgian State Gazette · acts
0 of 1 acts readWe know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.
Analysis
Financial profile
5 of 5 axes measuredMixed profile: strong on stability, weaker on solvency.
All 5 axes are computed from data Checked has read.
Credit advice
verdict per customer and amountSimilar
Similar companies
Comparable size, same sectorCompany registry
Company registry (CBE)
Crossroads Bank| Legal nameFR | Pharma Derasse BSI |